Thrombocytopenia after vaccination: Case reports to the US Vaccine Adverse Event Reporting System, 1990-2008

Vaccine

Volumn 29, Issue 6, 2011, Pages 1319-1323

  Woo, Emily Jane ^a   Wise, Robert P ^a   Menschik, David ^a   Shadomy, Sean V ^b   Iskander, John ^b   Beeler, Judy ^a   Varricchio, Frederick ^a   Ball, Robert ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Adverse event; Postmarketing safety; Thrombocytopenia; Vaccine

Indexed keywords

ANTHRAX VACCINE; CHICKENPOX MEASLES MUMPS RUBELLA VACCINE; CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE PLUS HEPATITIS B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; LYME DISEASE VACCINE; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; RABIES VACCINE; ROTAVIRUS VACCINE; RUBELLA VACCINE; TETANUS TOXOID; TYPHOID VACCINE; VARICELLA ZOSTER VACCINE; WART VIRUS VACCINE; YELLOW FEVER VACCINE;

ARTICLE; HUMAN; PRIORITY JOURNAL; THROMBOCYTOPENIA; VACCINATION;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; DRUG TOXICITY; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; THROMBOCYTOPENIA; UNITED STATES; VACCINATION; VACCINES; YOUNG ADULT;

EID: 78751567754     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.11.051     Document Type: Article

References (37)

1. Glanz J., France E., Xu S., Hayes T., Hambidge S. A population-based, multisite cohort study of the predictors of chronic idiopathic thrombocytopenic purpura in children. Pediatrics 2008, March (121)(3):e506-e512.
2. Cines D.B., Blanchette V.S. Immune thrombocytopenic purpura. N Engl J Med 2002, 346(March 28 (13)):995-1008.
3. Chu Y.W., Korb J., Sakamoto K.M. Idiopathic thrombocytopenic purpura. Pediatr Rev 2000, 21(March (3)):95-104.
4. Miller E., Waight P., Farrington C.P., Andrews N., Stowe J., Taylor B. Idiopathic thrombocytopenic purpura and MMR vaccine. Arch Dis Child 2001, 84(3):227-229.
5. Black C., Kaye J.A., Jick H. MMR vaccine and idiopathic thrombocytopaenic purpura. Br J Clin Pharmacol 2003, 55(1):107-111.
6. France E.K., Glanz J., Xu S., Hambidge S., Yamasaki K., Black S.B., et al. Vaccine Safety Datalink Team Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children. Pediatrics 2008, 121(March (3)):e687-e692.
7. Bertuola F., Morando C., Menniti-Ippolito F., Da Cas R., Capuano A., Perilongo G., et al. Association between drug and vaccine use and acute immune thrombocytopenia in childhood: a case-control study in Italy. Drug Saf 2010, 33(1):65-72.
8. Rajantie J., Zeller B., Treutiger I., Rosthöj S. NOPHO ITP working group and five national study groups. Vaccination associated thrombocytopenic purpura in children. Vaccine 2007, February 26 (25)(10):1838-1840.
9. Beeler J., Varricchio F., Wise R. Thrombocytopenia after immunization with measles vaccines: review of the vaccine adverse events reporting system (1990-1994). Pediatr Infect Dis J 1996, 15(1):88-90.
10. Varricchio F. The vaccine adverse event reporting system. J Toxicol Clin Toxicol 1998, 36(7):765-768.
11. Chaves S.S., Haber P., Walton K., Wise R.P., Izurieta H.S., Schmid D.S., et al. Safety of varicella vaccine after licensure in the United States: experience from reports to the vaccine adverse event reporting system, 1995-2005. J Infect Dis 2008, 197(March 1 (Suppl. 2)):S170-S177.
12. Wise R.P., Salive M.E., Braun M.M., Mootrey G.T., Seward J.F., Rider L.G., et al. Postlicensure safety surveillance for varicella vaccine. JAMA 2000, 284(10):1271-1279.
13. Sharrar R.G., LaRussa P., Galea S.A., Steinberg S.P., Sweet A.R., Keatley R.M., et al. The postmarketing safety profile of varicella vaccine. Vaccine 2000, 19(7-8):916-923.
14. Wise R.P., Iskander J., Pratt R.D., Campbell S., Ball R., Pless R.P., et al. Postlicensure safety surveillance for 7-valent pneumococcal conjugate vaccine. JAMA 2004, 13(292 (14)):1702-1710.
15. Code of Federal Regulations. 21 CFR 600.80. US Government Printing Office; 2001.
16. Varricchio F., Iskander J., Destefano F., Ball R., Pless R., Braun M.M., et al. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J 2004, 23(April (4)):287-294.
17. Iskander J.K., Miller E.R., Chen R.T. The role of the Vaccine Adverse Event Reporting system (VAERS) in monitoring vaccine safety. Pediatr Ann 2004, 33(September (9)):599-606.
18. Zhou W., Pool V., Iskander J.K., English-Bullard R., Ball R., Wise R.P., et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS) United States, 1991-2001. MMWR Surveill Summ 2003, 52(January 24 (1)):1-24.
19. Withdrawal of rotavirus vaccine recommendation. MMWR Morb Mortal Wkly Rep 1999, 48(43):1007.
20. Wise R.P., Bonhoeffer J., Beeler J., Donato H., Downie P., Matthews D., et al. Thrombocytopenia: case definition and guidelines for collection, analysis, and presentation of immunization safety data, Brighton Collaboration Thrombocytopenia Working Group. Vaccine 2007, 25(31):5717-5724.
21. Woo E.J., Ball R., Burwen D.R., Braun M.M. Effects of stratification on data mining in the US Vaccine Adverse Event Reporting System (VAERS). Drug Saf 2008, 31(8):667-674.
22. Evans S.J., Waller P.C., Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 2001, 10(6):483-486.
23. Empirica™ Signal. Phase forward. Waltham, MA.
24. Stratton K.R., Howe C.J., Johnston R.B. Adverse events associated with childhood vaccines other than pertussis and rubella. Summary of a report from the Institute of Medicine. JAMA 1994, 271(20):1602-1605.
25. Vaccine Safety Committee, Institute of Medicine. Adverse Events Associated with Childhood Vaccines: evidence bearing on casuality. In: Stratton KR, Howe CJ, Johnston RB, editors. Washington, DC: National Academy Press; 1994. http://www.hrsa.gov/osp/vicp/table.htm.
26. Oski F.A., Naiman J.L. Effect of live measles vaccine on the platelet count. N Engl J Med 1966, 275(7):352-356.
27. Vlacha V., Forman E.N., Miron D., Peter G. Recurrent thrombocytopenic purpura after repeated measles-mumps-rubella vaccination. Pediatrics 1996, 97(5):738-739.
28. Sauvé L.J., Bettinger J., Scheifele D., Halperin S., Vaudry W. Law B; Canadian Immunization Monitoring Program, and Active (IMPACT). Postvaccination thrombocytopenia in Canada. Pediatr Infect Dis J 2010, 29(June (6)):559-561.
29. Joutsi-Korhonen L., Javela K., Hormila P., Kekomaki R. Glycoprotein V-specific platelet-associated antibodies in thrombocytopenic patients. Clin Lab Haematol 2001, 23(5):307-312.
30. Gentilini G., Curtis B.R., Aster R.H. An antibody from a patient with ranitidine-induced thrombocytopenia recognizes a site on glycoprotein IX that is a favored target for drug-induced antibodies. Blood 1998, 92(7):2359-2365.
31. Cines D.B., Kaywin P., Bina M., Tomaski A., Schreiber A.D. Heparin-associated thrombocytopenia. N Engl J Med 1980, 303(October 2 (14)):788-795.
32. Acharya S., Bussel J.B. Hematologic toxicity of sodium valproate. J Pediatr Hematol Oncol 2000, 22(1):62-65.
33. Chen R.T., Glasser J.W., Rhodes P.H., Davis R.L., Barlow W.E., Thompson R.S., et al. Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team. Pediatrics 1997, 99(6):765-773.
34. National Vaccine Advisory Committee. Report on 2009 H1N1 Vaccine Safety Risk Assessment. http://www.hhs.gov/nvpo/nvac/reports/vsrawg_report_apr2010.html.
35. Banks D., Woo E.J., Burwen D.R., Perucci P., Braun M.M., Ball R. Comparing data mining methods on the VAERS database. Pharmacoepidemiol Drug Saf 2005, 14(9):601-609.
36. Almenoff J., Tonning J.M., Gould A.L., Szarfman A., Hauben M., Ouellet-Hellstrom R., et al. Perspectives on the use of data mining in pharmaco-vigilance. Drug Saf 2005, 28(11):981-1007.
37. FDA guidance for industry: good pharmacovigilance practices and pharmacoepidemiologic assessment. http://www.fda.gov/cder/guidance/6359OCC.htm.